Newsroom | 13197 results

Sorted by: Latest

Medical Supplies
-

Mosaic Reporting™ Passes 100,000 Daily Radiology Reports

NASHVILLE, Tenn.--(BUSINESS WIRE)--Mosaic Clinical Technologies, Inc.™ (Mosaic) today announced that exams reported by radiologists using Mosaic Reporting™, the AI-assisted reporting application within its MosaicOS platform, have surpassed 100,000 per day. First used clinically in April 2025 and then launched commercially to hospitals and health systems in June 2026. Mosaic developed the AI-assisted reporting software to address the inefficiencies and administrative burden associated with legac...
-

Cerus Corporation to Participate in Upcoming Investor Conferences

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that members of the Company’s management will participate in the following upcoming investor conferences. Citi’s 2026 Global Healthcare Conference Format: One-on-one meetings Date: Tuesday, December 1, 2026 Location: Miami, Florida Piper Sandler 38th Annual Healthcare Conference Format: One-on-one meetings Date: Wednesday, December 2, 2026 Location: New York, New York ABOUT CERUS Cerus Corporation is dedicated so...
-

C2N Diagnostics Expands Portfolio of Blood Tests with Next-Generation Brain Amyloid Assay for Clinical Researchers Studying Alzheimer’s Disease and Related Neurological Disorders

ST. LOUIS--(BUSINESS WIRE)--C2N Diagnostics, LLC, a pioneer in advanced diagnostic testing for brain health, announces the launch of a novel plasma multi-analyte assay (MAA) for amyloid beta (Aβ) protein using high-resolution mass spectrometry (LC-MS/MS). The C2N-Aβ-MAA (6x) precisely quantifies six Aβ peptide variants from a single plasma sample. The variants measured include Aβ37, Aβ38, Aβ39, Aβ40, Aβ42, and Aβ43. This ability to accurately quantitate six unique Aβ variants from one sample en...
-

Radical Catheter Technologies Announces FDA 510(k) Clearance of Reperfusion Catheters, Extending its Platform into Acute Ischemic Stroke Treatment

LOS GATOS, Calif.--(BUSINESS WIRE)--Radical Catheter Technologies announces FDA 510(k) clearance of Reperfusion Catheters, extending its platform into acute ischemic stroke treatment....
-

Enterprise Therapeutics Granted EMA Orphan Medicinal Product Designation for Novel Cystic Fibrosis Therapy, ETD001

BRIGHTON, England--(BUSINESS WIRE)--Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted ETD001 designation as an orphan medicinal product for the treatment of cystic fibrosis. This follows the announcement earlier this year of a positive Phase 2...
-

Retractable Technologies, Inc. Results for the Periods Ended September 30, 2026

LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE American: RVP) reports total net sales of $14.1 million for the third quarter of 2026 and an operating loss of $4.1 million for the period, as compared to total net sales for the same period last year of $10.1 million and an operating loss of $3.7 million. For the first nine months of the year, net sales were $28.5 million and operating losses were $15.5 million as compared to 2025 net revenues of $28.8 million and operatin...
-

KARL STORZ North America Earns Premier's 2026 Supplier Excellence Award for Surgical Services

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ North America earns Premier's 2026 Supplier Excellence Award....
-

Stevanato Group to Participate in Upcoming Investor Conferences

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in three upcoming investor conferences. The Company will participate in the Jefferies Global Healthcare Conference taking place from Monday, November 16, 2026, to Thursday, November 19, 2026, in London. The Company will host a...
-

Rejoni Announces First Commercial Case Using the Juveena® Hydrogel System at CCRM Fertility of New Jersey

BURLINGTON, Mass.--(BUSINESS WIRE)--Rejoni, Inc., a commercial-stage women's health company focused on uterine health, today announced that the first commercial procedure using the Juveena Hydrogel System has been performed by Serena H. Chen, MD, Founding Partner and Director of Advocacy, at CCRM Fertility of New Jersey in Livingston, N.J. Intrauterine adhesions (IUAs), the hallmark of Asherman's syndrome, form when the uterine lining is injured, most often after hysteroscopic surgery or uterin...
-

Henry Schein Updates Presentation of Non-GAAP Financial Measures

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, today announced an update to its presentation of certain non-GAAP financial measures. Beginning with its fourth-quarter 2026 financial results, Henry Schein will exclude the gains resulting from the remeasurement to fair value of previously held equity interests from its non-GAAP financial results. These gains arise when the...